Shernan G. Holtan

TL;DR: A novel composite end point of GV HD-free/relapse-free survival (GRFS) in which events include grade 3-4 acute GVHD, systemic therapy-requiring chronic GVhd, relapse, or death in the first post-HCT year is examined.

TL;DR: In this article, a review summarizes the similarities between growth and immune privilege in cancer and pregnancy and identifies areas for further investigation, and the knowledge gained from analyzing similarities and differences between the physiologic state of pregnancy and the pathology of cancer could lead to identification of new potential targets for cancer therapeutic agents.

TL;DR: In this review, recent discoveries in the context of current aGVHD care are highlighted, including small molecules regulating immunologic checkpoints, enhancement of suppressor cytokines and cellular subsets, modulation of the microbiota, graft manipulation, and other donor-based prophylaxis strategies.

TL;DR: In this paper, the authors developed a novel acute graft-versus-host disease (GVHD) risk score using clinical grouping, descriptive statistics and recursive partitioning to identify poorly responsive, high-risk (HR) acute GVHD by the number of involved organs and severity.

TL;DR: This prospective multicentre phase 2 trial evaluated regimens using either maraviroc, bortezomib, or post-transplantation cyclophosphamide for GvHD prophylaxis compared with controls receiving the combination of tacrolimus and methotrexate to identify the most promising intervention to be further tested in a phase 3 trial.